MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The company's proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. The company also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing. Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. The company sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MDXG
Previous Symbol
CUSIPN/A
Phone770-651-9100
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E Ratio13.33
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$245.01 million
Price / Sales0.70
Cash Flow$0.1006 per share
Price / Cash Flow15.40
Book Value$1.21 per share
Price / Book1.28
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares111,040,000
Market Cap$310.90 million
OptionableOptionable
MiMedx Group (NASDAQ:MDXG) Frequently Asked Questions
What is MiMedx Group's stock symbol?
MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."
How will MiMedx Group's stock buyback program work?
MiMedx Group announced that its Board of Directors has authorized a stock repurchase plan on Wednesday, December 13th 2017, which allows the company to buyback $10,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company's board believes its shares are undervalued.
How were MiMedx Group's earnings last quarter?
MiMedx Group Inc (NASDAQ:MDXG) issued its quarterly earnings results on Thursday, October, 26th. The medical equipment provider reported $0.08 earnings per share for the quarter, hitting analysts' consensus estimates of $0.08. The medical equipment provider earned $84.60 million during the quarter, compared to analysts' expectations of $84.60 million. MiMedx Group's revenue was up 31.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.06 EPS. View MiMedx Group's Earnings History.
When is MiMedx Group's next earnings date?
What price target have analysts set for MDXG?
3 brokerages have issued 12 month target prices for MiMedx Group's stock. Their predictions range from $9.00 to $9.00. On average, they anticipate MiMedx Group's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 480.6% from the stock's current price. View Analyst Price Targets for MiMedx Group.
What is the consensus analysts' recommendation for MiMedx Group?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MiMedx Group.
Has MiMedx Group been receiving favorable news coverage?
News articles about MDXG stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. MiMedx Group earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are some of MiMedx Group's key competitors?
Some companies that are related to MiMedx Group include K2M Group (KTWO), Nevro (NVRO), Luminex (LMNX), AtriCure (ATRC), Cryolife (CRY), Orthofix Medical (OFIX), Cardiovascular Systems (CSII), Intersect ENT (XENT), Tactile Systems Technology (TCMD), AngioDynamics (ANGO), Cerus (CERS), SurModics (SRDX), OraSure Technologies (OSUR), SI-Bone (SIBN) and LeMaitre Vascular (LMAT).
Who are MiMedx Group's key executives?
MiMedx Group's management team includes the folowing people:
- Ms. Alexandra O. Haden, Gen. Counsel and Sec. (Age 43)
- Mr. David J. Coles, Interim Chief Exec. Officer (Age 53)
- Mr. Edward J. Borkowski, Interim Chief Financial Officer (Age 60)
- Dr. Thomas J. Koob, Chief Scientific Officer (Age 69)
- Mr. Thornton A. Kuntz Jr., Sr. VP of Admin. (Age 64)
Who are MiMedx Group's major shareholders?
MiMedx Group's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.48%), Vanguard Group Inc (7.75%), Vanguard Group Inc. (7.75%), Bank of New York Mellon Corp (1.65%), Wells Fargo & Company MN (1.00%) and Nordea Investment Management AB (0.71%). View Institutional Ownership Trends for MiMedx Group.
Which institutional investors are selling MiMedx Group stock?
MDXG stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, BlackRock Inc., Thrivent Financial for Lutherans, Strs Ohio, Prudential Financial Inc., Russell Investments Group Ltd., Alps Advisors Inc. and Thompson Investment Management Inc.. View Insider Buying and Selling for MiMedx Group.
Which institutional investors are buying MiMedx Group stock?
MDXG stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc, Vanguard Group Inc., Nordea Investment Management AB, Wells Fargo & Company MN, Morgan Stanley, Bank of New York Mellon Corp, GSA Capital Partners LLP and D.A. Davidson & CO.. View Insider Buying and Selling for MiMedx Group.
How do I buy shares of MiMedx Group?
Shares of MDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MiMedx Group's stock price today?
One share of MDXG stock can currently be purchased for approximately $1.55.
How big of a company is MiMedx Group?
MiMedx Group has a market capitalization of $310.90 million and generates $245.01 million in revenue each year.
What is MiMedx Group's official website?
How can I contact MiMedx Group?
MiMedx Group's mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The medical equipment provider can be reached via phone at 770-651-9100 or via email at [email protected]
MarketBeat Community Rating for MiMedx Group (NASDAQ MDXG)
MarketBeat's community ratings are surveys of what our community members think about MiMedx Group and other stocks. Vote "Outperform" if you believe MDXG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDXG will underperform the S&P 500 over the long term. You may vote once every thirty days.
